Abbott Laboratories (ABT) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) came in at $1.30, slightly below Wall Street's consensus estimate of $1.31. Additionally, revenue reached $11.4 billion, falling short of the expected $11.5 billion.
The company will host an earnings conference call at BMO to discuss these results and provide further insights into its business performance. This update provides insight into Abbott Laboratories' recent operational challenges and financial health, as missing analyst expectations may reflect underlying issues in the business or broader market conditions.
Investors are encouraged to review the full earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance and future outlook.
Abbott Laboratories, headquartered in Abbott Park, Illinois, engages in the discovery, development, manufacture, and sale of healthcare products. The company operates across various segments, including Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. With a market cap of $218.34 billion and a P/E ratio of 15.62, Abbott employs approximately 114,000 people and serves customers in over 160 countries. Upcoming earnings are scheduled for April 13, 2026, with an EPS estimate of $1.2143 and revenue expectation of $11.3 billion.